{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:39:30Z","timestamp":1793104770027,"version":"4.5.0"},"reference-count":41,"publisher":"Massachusetts Medical Society","issue":"7","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"name":"TaiMed Biologics"},{"name":"Theratechnologies"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2018,8,16]]},"DOI":"10.1056\/nejmoa1711460","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T17:01:23Z","timestamp":1534352483000},"page":"645-654","source":"Crossref","is-referenced-by-count":222,"title":["Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1"],"prefix":"10.1056","volume":"379","author":[{"given":"Brinda","family":"Emu","sequence":"first","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Fessel","sequence":"additional","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Schrader","sequence":"additional","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy","family":"Kumar","sequence":"additional","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Richmond","sequence":"additional","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Win","sequence":"additional","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Weinheimer","sequence":"additional","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marsolais","sequence":"additional","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Lewis","sequence":"additional","affiliation":[{"name":"From the Yale School of Medicine, New Haven, CT (B.E.); Kaiser Foundation Research Institute (J.F.) and Quest Clinical Research (S. Win), San Francisco; Schrader Clinic, Houston (S.S.); Georgetown University, Washington, DC (P.K.); Nova Southeastern University, Ft. Lauderdale, FL, and Florida International University, Miami (G.R.); TaiMed Biologics, Irvine, CA (S. Weinheimer, S.L.); and Theratechnologies, Montreal (C.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318134257a"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200205030-00010"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200404300-00005"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-091212-153406"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit697"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1710608"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv120"},{"key":"e_1_3_4_9_2","unstructured":"Kim DZR Saduvala N et al. Trend in transmitted HIV-1 ARV drug resistance-associated Mutations: 10 HIV surveillance areas US 2007-2010. Presented at the 20th Conference on Retroviruses and Opportunistic Infections Atlanta March 3\u20136 2013. abstract."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-011-9942-x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00831"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit017"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq101"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030356"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000174455.01369.ad"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/312763a0"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.149.5.1779"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1997.13.933"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.8.4784-4793.1992"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2010.09.017"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(02)00002-1"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1993.9.199"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.03.255"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00942-08"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182732746"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02237-10"},{"key":"e_1_3_4_27_2","unstructured":"Khanlou H Gathe J Schrader S Towner WJ Weinheimer SP Lewis ST. Safety efficacy and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago September 17\u201320 2011. abstract."},{"key":"e_1_3_4_28_2","unstructured":"Norris D Morales J Gathe J et al. Phase 2 efficacy and safety of the novel entry inhibitor TNX-355 in combination with optimized background regimen (OBR). Presented at the XVI International AIDS Conference Toronto August 13\u201318 2006. abstract."},{"key":"e_1_3_4_29_2","unstructured":"Norris D Morales J Godofsky E Garcia F Hardwicke R Lewis ST. TNX-355 in combination with optimized background regimen (OBR) achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks. Presented at the XVI International AIDS Conference Toronto August 13\u201318 2006. abstract."},{"key":"e_1_3_4_30_2","unstructured":"Guidance for industry \u2014 human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Silver Spring MD: Food and Drug Administration November 2015 (https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm355128.pdf)."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00177-0"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.09.010"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0006"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002537"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035211"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708975"},{"key":"e_1_3_4_38_2","first-page":"49","article-title":"Immune reconstitution inflammatory syndrome in HIV-infected patients.","volume":"7","author":"Walker NF","year":"2015","unstructured":"Walker NF, Scriven J, Meintjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl) 2015;7:49-64.25709503","journal-title":"HIV AIDS (Auckl)"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1029917"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70026-8"},{"key":"e_1_3_4_41_2","unstructured":"Orphan drug designations and approvals: ibalizumab (Trogarzo). Silver Spring MD: Food and Drug Administration (https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=321910)."},{"key":"e_1_3_4_42_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington DC: Department of Health and Human Services (http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf)."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1711460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:41:07Z","timestamp":1711485667000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1711460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,8,16]]}},"alternative-id":["10.1056\/NEJMoa1711460"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa1711460","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]}}}